A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study is testing a new medicine called bomedemstat for a blood condition known as essential thrombocythemia, or ET. ET causes your body to make too many platelets, which are tiny cells that help blood clot. The study is for people who have ET and whose usual medicine, hydroxyurea, isn't helping enough or is causing difficult side effects. We want to find out if bomedemstat is more effective and safer than other available treatments like Anagrelide, Busulfan, Interferon alfa, or Ruxolitinib. By comparing these treatments, the researchers hope to offer better options for managing this condition. The main goal is to see if bomedemstat can lead to a lasting improvement in symptoms and blood counts.
En un coup d'œil
De quoi parle cette étude ?
This study is about a blood condition called essential thrombocythemia, often shortened to ET. In ET, your body produces too many small blood cells called platelets. While platelets are important for stopping bleeding, having too many can sometimes lead to serious problems like blood clots or, less commonly, bleeding issues. Many people with ET take a medicine called hydroxyurea to help control their platelet levels.
However, for some people, hydroxyurea either stops working well or causes side effects that are difficult to manage. This study is for those individuals. Researchers want to compare a new medicine, bomedemstat, with other established treatments already used for ET, such as Anagrelide, Busulfan, Interferon alfa, or Ruxolitinib. They want to find out if bomedemstat is a better option for people whose previous treatment isn't quite right.
The main aim is to see if bomedemstat can provide a more lasting and effective control of platelet counts and other symptoms of ET, compared to what is currently available. This is a "Phase 3" study, which means it's one of the final steps in testing a new medicine before it can potentially be made widely available. It's a large study designed to confirm the safety and benefits of bomedemstat.
Points clés
- Tests a new medicine (bomedemstat) for essential thrombocythemia (ET).
- For ET patients whose current treatment (hydroxyurea) isn't working or causing problems.
- Compares bomedemstat to other standard ET treatments.
- Aims to find a more lasting and effective way to manage ET.
- Requires regular hospital visits and monitoring.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To join this study, you must be an adult aged 18 or over and have been diagnosed with essential thrombocythemia (ET) by an expert. You would also need to have received hydroxyurea for your ET in the past, but it either didn't work well enough, or you couldn't tolerate its side effects.
Your bone marrow, which is where blood cells are made, should show only minor changes related to ET. Your platelet count must also be above 450 (x 10^9/L) just before starting the study medicine. You also need to have a certain level of white blood cells (specifically, neutrophils) of at least 0.75 (x 10^9/L).
There are also some reasons why you might not be able to join. For example, if you've had a bad allergic reaction to medicines similar to bomedemstat or to any of the other treatments being compared. If you have stomach or gut problems that might stop the medicine from being absorbed properly, or if you have a high risk of bleeding, you might not be eligible. If you've had certain types of cancer in the last two years, this might also prevent you from joining, though some very common and easily treated skin cancers (like basal cell carcinoma) wouldn't stop you.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have a diagnosis of essential thrombocythemia (ET)?
- Has hydroxyurea stopped working well for your ET, or did you have bad side effects from it?
- Is your platelet count currently high (above 450)?
- Do you have good general health, without severe gut issues or high bleeding risk?
En quoi consiste la participation ?
If you join this study, you’ll receive either the new medicine, bomedemstat, or one of the existing best available treatments for ET. Your treatment will be decided by chance, like flipping a coin. You'll have regular hospital visits for check-ups, blood tests, and to discuss any side effects you might be experiencing. These visits will help the doctors monitor your health and how the treatment is working. The study is designed to measure how safe and effective the treatments are over time. The exact number and frequency of visits, as well as the total length of your participation, will be explained in detail by the study team. You'll be given all the study medication as part of your participation.
Risques et avantages potentiels
Locations (161)
- Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)Code postal vérifiéGlendale, United States
- Los Angeles Cancer Network ( Site 3491)Code postal vérifiéGlendale, United States
- Stanford Cancer Institute ( Site 0107)Code postal vérifiéStanford, United States
- The Lundquist Institute ( Site 3423)Code postal vérifiéTorrance, United States
- University of Colorado Anschutz Medical Campus ( Site 3425)Code postal vérifiéAurora, États-Unis
- Tufts Medical Center ( Site 3408)Code postal vérifiéBoston, États-Unis
- University of Michigan ( Site 0008)Code postal vérifiéAnn Arbor, États-Unis
- Henry Ford Hospital ( Site 3413)Code postal vérifiéDetroit, United States
- Optum Care Cancer Center ( Site 3497)Code postal vérifiéLas Vegas, United States
- Roswell Park Cancer Institute ( Site 3421)Code postal vérifiéBuffalo, United States
- Duke University Health System (DUHS) ( Site 0016)Code postal vérifiéDurham, États-Unis
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)Code postal vérifiéWinston-Salem, United States
Questions fréquentes
What is essential thrombocythemia (ET)?
ET is a condition where your body makes too many platelets, which are blood cells that help with clotting. This can sometimes lead to blood clots or bleeding issues.
What is bomedemstat?
Bomedemstat is a new medicine being tested in this study for people with ET who haven't responded well to standard treatments or experienced side effects.
Will I definitely receive bomedemstat if I join?
Not necessarily. Participants will be randomly assigned to receive either bomedemstat or one of the established treatments currently used for ET.
What kind of commitment is joining the study?
You'll have regular hospital visits for check-ups, blood tests, and to get your study medication. The study team will explain the full schedule.
Puis-je quitter l'étude si je change d'avis ?
Yes, you have the right to leave the study at any time, for any reason, and it won't affect your ongoing medical care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.